Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Brigham and Women's Hospital
MedSIR
MedSIR
Yale University
Hoffmann-La Roche
Roswell Park Cancer Institute
Stanford University
University of Rochester
Beijing Biostar Pharmaceuticals Co., Ltd.
MedSIR
Biogen
Fudan University
Guangzhou Medical University
Stanford University
Tongji Hospital
Fudan University
National Cancer Institute (NCI)
Seagen Inc.
Hoffmann-La Roche
Washington University School of Medicine
Duke University
Fudan University
Sun Yat-sen University
Jules Bordet Institute
US Oncology Research
Dana-Farber Cancer Institute
National Taiwan University Hospital
Eli Lilly and Company
DEKK-TEC, Inc.
Case Comprehensive Cancer Center
Institut Paoli-Calmettes
Angiochem Inc
Novartis
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Fudan University
ChineseAMS
UNC Lineberger Comprehensive Cancer Center
M.D. Anderson Cancer Center
University of California, San Francisco
AIO-Studien-gGmbH
University of Washington
Merck Sharp & Dohme LLC
Angiochem Inc
Sanofi
Memorial Sloan Kettering Cancer Center
GlaxoSmithKline
Hellenic Cooperative Oncology Group
Baylor Breast Care Center
Jules Bordet Institute